Comparative Pharmacology
Head-to-head clinical analysis: FORTAZ IN PLASTIC CONTAINER versus ROCEPHIN KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORTAZ IN PLASTIC CONTAINER versus ROCEPHIN KIT.
FORTAZ IN PLASTIC CONTAINER vs ROCEPHIN KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ceftazidime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP3, thereby disrupting peptidoglycan cross-linking and leading to cell lysis. It is a third-generation cephalosporin with broad-spectrum activity against Gram-negative bacteria, including Pseudomonas aeruginosa.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking, leading to cell lysis and death.
1-2 g IV/IM every 8-12 hours; maximum 6 g/day.
Adult: 1-2 g IV or IM every 24 hours. Maximum 4 g/day for severe infections.
None Documented
None Documented
1.8 hours in normal adults; prolonged to 3-5 hours in neonates and 10-30 hours in severe renal impairment (CrCl <10 mL/min)
Terminal half-life 6-9 hours in healthy adults; prolonged to 12-15 hours in elderly and up to 30 hours in severe renal impairment (CrCl <10 mL/min).
Primarily renal (80-90% unchanged) via glomerular filtration and tubular secretion; minor biliary/fecal (<10%)
Renal (33-67% unchanged), biliary (40-50% as active drug and metabolites), fecal (minor).
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic